vTv Therapeutics, which laid off 65% of its workforce in December, announced Rich Martin has taken over as acting CEO. Board member resigns from vTv Therapeutics ...
As the value comeback story continues to play out in the capital markets, ETF investors can join in with funds like the Vanguard Value ETF (VTV). VTV focuses primarily on large cap value stocks that ...
vTv Therapeutics has cut 65% of its workforce in a company restructuring to prioritize the development of an orally administered Type 1 Diabetes treatment. A Triad clinical-stage pharmaceutical ...
High Point’s vTv Therapeutics Inc. has received the U.S. Food and Drug Administration designation as a Breakthrough Therapy for its TTP399 oral supplement treating type 1 diabetes and psoriasis.
The narrative of a value comeback goes on, with increasing capital flows into value-based ETFs. Investors and advisors alike will want to consider funds like the Vanguard Value ETF (VTV). VTV exhibits ...
HIGH POINT, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an ...
Vanguard Value Index Fund ETF Shares maintains strong returns and momentum, delivering an 11% total return year to date with low risk. VTV's portfolio strength lies in financials, health care, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback